Related Experiment Video

Updated: Sep 15, 2025

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Chickpea attenuates postprandial blood glucose responses: a systematic review and meta-analysis

Eunice Mah¹, Cassi N Uffelman¹, Traci M Blonquist¹

¹Biofortis, Inc, Addison, IL, USA.

Nutrition Journal

|July 14, 2025

Abstract

Background:

Chickpeas are a legume that may help improve glycemic control, but their acute effects on postprandial glucose and insulin responses are unclear. This systematic review and meta-analysis aimed to assess the impact of acute chickpea consumption on these outcomes in controlled, crossover trials.

Methods:

We screened PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase from inception through March 21, 2024 for acute, controlled, experimental (randomized or non-randomized) trials comparing chickpea consumption with carbohydrate-matched controls that reported on postprandial glucose and insulin responses (iAUC and C_max). Two reviewers extracted the data and assessed risk-of-bias (RoB 2) and certainty-of-evidence (GRADE). Data were analyzed using generic inverse-variance with random-effects model.

Results:

A total of 28 eligible studies (40 comparisons) were identified. Chickpea consumption significantly reduced postprandial glucose iAUC compared to carbohydrate-matched controls (MD: -47.89, 95% CI: -64.20, -31.58, p < 0.0001). No significant effects were observed on glucose C_max (MD: -0.23, 95% CI: -1.48, 1.02, p = 0.7207) or insulin iAUC (MD: 50.06, 95% CI: -3771.14, 3871.26, p = 0.9795). The GRADE assessment indicated very low certainty for glucose iAUC due to heterogeneity.

Conclusion:

Meta-analysis of controlled trials suggest that acute chickpea consumption lowers postprandial glucose iAUC, albeit with low certainty of evidence. While no significant effects were observed on glucose peak or insulin response, the findings align with previous research on pulses and glycemic control. Further high-quality studies are needed to confirm these findings, as the current evidence is of low to very low certainty. Future studies should explore the long-term effects of chickpea consumption, investigate the impact of processing methods, and include metabolically unhealthy populations to enhance generalizability.

Registration:

This review was registered on PROSPERO (CRD42022365074).

Keywords:

Blood sugar Cicer arietinum Garbanzo Healthy adults Legumes

More Related Videos

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Hormones Regulating Blood Glucose

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

Cell Specific Gene Expression

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Articles linked to this work by shared authors, journal, and citation graph.

Oral Fructanase Administration Reduces Gastrointestinal Symptom Severity after Acute Inulin Challenge in Healthy Adults.

The Journal of nutrition·2026

Use of a Personalized Digital Wellness App to Increase Employee Engagement Without Financial Incentives.

Journal of occupational and environmental medicine·2026

What Drives Consumers' Breakfast Food Choices? Case Study in South Africa-A Multiethnic Middle-Income Country.

Foods (Basel, Switzerland)·2026

Arsenic, cadmium, lead, mercury, and PFAS exposure during pregnancy or lactation and respective concentrations in human milk: Systematic review.

Environmental research·2025

School Staff Perspectives on Tobacco Prevention: Findings From a Statewide Educator Survey.

Health education & behavior : the official publication of the Society for Public Health Education·2025

Red meat intake and its influences on inflammation and immune function biomarkers in human adults: a systematic review and meta-analysis of randomized controlled trials and observational studies.

Critical reviews in food science and nutrition·2025

See all related articles